- Home
- STFS vs PHGE Comparison
STFS vs PHGE Comparison
Compare STFS & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STFS
- PHGE
- Stock Information
- Founded
- STFS 2015
- PHGE 2015
- Country
- STFS China
- PHGE Israel
- Employees
- STFS N/A
- PHGE N/A
- Industry
- STFS
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- STFS
- PHGE Health Care
- Exchange
- STFS NYSE
- PHGE Nasdaq
- Market Cap
- STFS 11.9M
- PHGE 13.3M
- IPO Year
- STFS 2024
- PHGE N/A
- Fundamental
- Price
- STFS $1.16
- PHGE $0.61
- Analyst Decision
- STFS
- PHGE Strong Buy
- Analyst Count
- STFS 0
- PHGE 2
- Target Price
- STFS N/A
- PHGE $23.00
- AVG Volume (30 Days)
- STFS 186.4K
- PHGE 191.6K
- Earning Date
- STFS 02-14-2025
- PHGE 05-19-2025
- Dividend Yield
- STFS N/A
- PHGE N/A
- EPS Growth
- STFS 43.38
- PHGE N/A
- EPS
- STFS 0.15
- PHGE N/A
- Revenue
- STFS $14,972,726.00
- PHGE N/A
- Revenue This Year
- STFS N/A
- PHGE N/A
- Revenue Next Year
- STFS N/A
- PHGE N/A
- P/E Ratio
- STFS $7.52
- PHGE N/A
- Revenue Growth
- STFS 57.60
- PHGE N/A
- 52 Week Low
- STFS $0.80
- PHGE $0.48
- 52 Week High
- STFS $17.91
- PHGE $4.99
- Technical
- Relative Strength Index (RSI)
- STFS N/A
- PHGE 54.10
- Support Level
- STFS N/A
- PHGE $0.52
- Resistance Level
- STFS N/A
- PHGE $0.57
- Average True Range (ATR)
- STFS 0.00
- PHGE 0.05
- MACD
- STFS 0.00
- PHGE 0.01
- Stochastic Oscillator
- STFS 0.00
- PHGE 80.46
About STFS STAR FASHION CULTURE HOLDINGS LIMITED
Star Fashion Culture Holdings Ltd is a content marketing solutions services provider. The company offer services focusing on marketing campaign planning and execution, offline advertising services; and online precision marketing services. The services also include marketing campaign planning and execution, events including marathons, sports events, and music festivals.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.